Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IL-33 acts as a costimulatory signal to generate alloreactive Th1 cells in graft-versus-host disease
Gaelen K. Dwyer, … , Warren Shlomchik, Hēth R. Turnquist
Gaelen K. Dwyer, … , Warren Shlomchik, Hēth R. Turnquist
Published May 3, 2022
Citation Information: J Clin Invest. 2022;132(12):e150927. https://doi.org/10.1172/JCI150927.
View: Text | PDF
Research Article Immunology

IL-33 acts as a costimulatory signal to generate alloreactive Th1 cells in graft-versus-host disease

  • Text
  • PDF
Abstract

Antigen-presenting cells (APCs) integrate signals emanating from local pathology and program appropriate T cell responses. In allogeneic hematopoietic stem cell transplantation (alloHCT), recipient conditioning releases damage-associated molecular patterns (DAMPs) that generate proinflammatory APCs that secrete IL-12, which is a driver of donor Th1 responses, causing graft-versus-host disease (GVHD). Nevertheless, other mechanisms exist to initiate alloreactive T cell responses, as recipients with disrupted DAMP signaling or lacking IL-12 develop GVHD. We established that tissue damage signals are perceived directly by donor CD4+ T cells and promoted T cell expansion and differentiation. Specifically, the fibroblastic reticular cell–derived DAMP IL-33 is increased by recipient conditioning and is critical for the initial activation, proliferation, and differentiation of alloreactive Th1 cells. IL-33 stimulation of CD4+ T cells was not required for lymphopenia-induced expansion, however. IL-33 promoted IL-12–independent expression of Tbet and generation of Th1 cells that infiltrated GVHD target tissues. Mechanistically, IL-33 augmented CD4+ T cell TCR-associated signaling pathways in response to alloantigen. This enhanced T cell expansion and Th1 polarization, but inhibited the expression of regulatory molecules such as IL-10 and Foxp3. These data establish an unappreciated role for IL-33 as a costimulatory signal for donor Th1 generation after alloHCT.

Authors

Gaelen K. Dwyer, Lisa R. Mathews, José A. Villegas, Anna Lucas, Anne Gonzalez de Peredo, Bruce R. Blazar, Jean-Philippe Girard, Amanda C. Poholek, Sanjiv A. Luther, Warren Shlomchik, Hēth R. Turnquist

×

Figure 6

IL-33 stimulation augments early donor CD4+ T cell activation.

Options: View larger image (or click on image) Download as PowerPoint
IL-33 stimulation augments early donor CD4+ T cell activation.
(A–G) CD3...
(A–G) CD3+ T cells from CD45.2+ CD4-Cre×R26-LSL-YFP×St2fl/fl (ST2fl/fl) B6 (1 × 106) and St2+/+ CD45.1+ (ST2WT) B6 (1 × 106) mice were labeled with CTV and cotransferred with 1 × 107 WT B6 TCD-BM into lethally irradiated BALB/c and B6 recipients. T cells were isolated from the spleens on d1, d2, d3, d5, and d7 and assessed by flow cytometry. (A) Representative CD69 expression on ST2WT (red) CD45.1+CTV+ or ST2fl/fl (blue) CD45.2+CTV+ donor CD4+ T cells from the same allo recipient spleen on d1. (B) Quantification of CD69 MFI on CD45.1+ or CD45.2+ CTV+ donor CD4+ T cells from allo recipient spleens on d1. (C) Quantification of frequency of CD45.1+ or CD45.2+CTV+ donor CD69+ CD4T cells at d1. (D) Representative plot (CTV versus CD62L) and histogram of CD62L expression on ST2WT (red) or ST2fl/fl (blue) donor CD4+ T cells from an allo recipient spleen on d3. (E) Quantification of CD62L MFI on d3, d5, and d7. (F) Representative plot (CTV versus CD44) and histogram of CD44 expression on ST2WT (red) or ST2fl/fl (blue) donor CD4+ T cells from an allo recipient spleen on d3. (G) Quantification of CD44 MFI on d3, d5, and d7. Data shown in B–G are represented as mean ± SD. n = 3–4/group. Data are representative of 2 experiments. *P < 0.05; **P < 0.01; ***P <0.001, 1-way ANOVA (B and C); 2-way ANOVA (E and G).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts